Pfaar Oliver, Gehrt Francesca, Li Hansen, Rudhart Stefan A, Nastev Alexander, Stuck Boris A, Hoch Stephan
The two first authors have equally contributed to the publication.
Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.
Allergol Select. 2021 Feb 24;5:119-127. doi: 10.5414/ALX02205E. eCollection 2021.
Allergic rhinitis (AR) is the most common IgE-mediated allergic disease. Multiple clinical trials have demonstrated promising results on the AR treatment with biologics, in particular with the use of omalizumab - an anti-IgE antibody. Omalizumab has also been established in the routine management of allergic asthma and chronic idiopathic urticaria. However, currently there is no approved license for the use of biologics in AR in Germany.
A systematic literature review has been completed including randomized controlled trials, meta-analyses, and reviews on the treatment of AR with omalizumab.
The systematic review demonstrates strong evidence supporting the use of omalizumab in the treatment of AR with regard to symptom control, safety profile, and management of comorbidities.
Omalizumab is a good and safe option in the treatment of AR in terms of symptom control and the management of pre-existing comorbidities. Further clinical trials with other biologics in the management of AR are needed and are expected to follow soon.
变应性鼻炎（AR）是最常见的IgE介导的过敏性疾病。多项临床试验已证明生物制剂治疗AR取得了令人鼓舞的结果，尤其是使用奥马珠单抗——一种抗IgE抗体。奥马珠单抗也已被用于过敏性哮喘和慢性特发性荨麻疹的常规治疗。然而，目前在德国，生物制剂用于AR的治疗尚未获得批准许可。
完成了一项系统的文献综述，纳入了关于奥马珠单抗治疗AR的随机对照试验、荟萃分析和综述。
该系统综述显示了有力证据，支持奥马珠单抗在症状控制、安全性和合并症管理方面用于AR的治疗。
就症状控制和既有合并症的管理而言，奥马珠单抗是治疗AR的一种安全有效的选择。需要并有望很快开展其他生物制剂治疗AR的进一步临床试验。
